macrossluvsrobotech
Nov 21, 5:27 PM
$LXRX First-principles science for Q1 2027: Across ~20,000 patients spanning every heart-adjacent malady under the sun—heart failure, diabetes, CKD, overweight & thrombosis—sotagliflozin 400 mg once daily cut broad CV/HF events by 30%—separates from placebo by Day 27–95. Now Phase 3 SONATA-HCM aims that exact 400 mg daily ceiling at ONE specific diagnosis with ZERO FDA-approved drugs: non-obstructive HCM (nHCM).
Why zeroing in stacks the odds in our favor:
• Less noise, sharper signal: Broad HF syndromes dilute drug effects across dozens of competing illnesses. Focusing 400 mg onto stiff, energy-starved nHCM (542 pts: 440 nHCM / 102 oHCM) concentrates the full biomechanical hit over 26 weeks.
• Tri-organ 400 mg power: Kidneys (SGLT2) unload fluid/pressure; gut (SGLT1) smooths glucose & boosts GLP-1; heart muscle (direct SGLT1) aids relaxation, restores energy & cuts micro-clots.
One simple daily pill (200, after 2 wks→ 400 mg), REMS-free, no CMI boxed warning.
$BIB $VTRS $NVO $LLY
0 replies